Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Plasma exchange for acute and acute-on-chronic liver failure: A systematic review and meta-analysis
Mohamed, Mouhand , Shaear, Mohammad , Nayfeh, Tarek , Mhanna, Mohammed , Srour, Omar, Nawras, Mohamad , Mentrose, Jonathan A., Assaly, Ragheb , Kubal, Chandrashekhar A. , Ghabril, Marwan , Patidar, Kavish R. , Kubal, Chandrashekhar A , Ghabril, Marwan S , Hernaez, Ruben , Mohamed, Mouhand F H , Nayfeh, Tarek , Patidar, Kavish R , Beran, Azizullah

Mayo Clinic

Liver Transplantation | August 2, 2023 | Volume: 30 | Issue: 2 | Pages: 127-141

10.1097/lvt.0000000000000231 | PMID 37530812 Get It

Plasma exchange (PE) is a promising therapeutic option in patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). However, the impact of PE on patient survival in these syndromes is unclear. We aimed to systematically investigate the use of PE in patients with ALF and ACLF compared with standard medical therapy (SMT). We searched PubMed/Embase/Cochrane databases to include all studies comparing PE versus SMT for patients ≥ 18 years of age with ALF and ACLF. Pooled risk ratios (RR) with corresponding 95% CIs were calculated by the Mantel-Haenszel method within a random-effect model. The primary outcome was 30-day survival for ACLF and ALF. Secondary outcomes were overall and 90-day survival for ALF and ACLF, respectively. Five studies, including 343 ALF patients (n = 174 PE vs. n = 169 SMT), and 20 studies, including 5,705 ACLF patients (n = 2,856 PE vs. n = 2,849 SMT), were analyzed. Compared with SMT, PE was significantly associated with higher 30-day (RR 1.41, 95% CI 1.06–1.87, p = 0.02) and overall (RR 1.35, 95% CI 1.12–1.63, p = 0.002) survival in ALF patients. In ACLF, PE was also significantly associated with higher 30-day (RR 1.36, 95% CI 1.22–1.52, p < 0.001) and 90-day (RR 1.21, 95% CI 1.10–1.34, p < 0.001) survival. On subgroup analysis of randomized controlled trials, results remained unchanged in ALF, but no differences in survival were found between PE and SMT in ACLF. In conclusion, PE is associated with improved survival in ALF and could improve survival in ACLF. PE may be considered in managing ALF and ACLF patients who are not liver transplant (LT) candidates or as a bridge to LT in otherwise eligible patients. Further randomized controlled trials are needed to confirm the survival benefit of PE in ACLF.
Recent Advances in Temporomandibular Joint Surgery
Wroclawski, Catherine, Mediratta, Jai Kumar , Fillmore, W. Jonathan

Mayo Clinic

Medicina | August 2, 2023 | Volume: 59 | Issue: 8 | Pages: 1409

10.3390/medicina59081409 | PMID 37629699 Get It

Temporomandibular disorders (TMDs) affect a high percentage of children and adults worldwide. Surgery may be indicated in severe or recalcitrant cases. Several recent advancements in TMD and temporomandibular joint (TMJ) surgery have elevated understanding and the ability to treat affected patients. We discuss recent advances in TMD epidemiology, juvenile idiopathic arthritis (JIA) of the TMJ, and surgical techniques and technologies. Technical advancements have been identified in TMJ arthroscopy, the treatment of TMJ subluxation and dislocation, and extended prosthetic total TMJ reconstruction (eTMJR). Overall, this review provides valuable insights into significant recent advancements in TMJ disorders and their surgical management.
Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn’s Disease Clinical Trials
Crowley, Eileen , Ma, Christopher , Guizzetti, Leonard, Lewindon, Peter , Gee, Michael S. , Hyams, Jeffrey S. , Rosen, Michael J. , Allmen, Daniel von, Overstraeten, Anthony de Buck van , Shackelton, Lisa M. , Rémillard, Julie, Schleicher, Lauren S., Rimola, Jordi , Taylor, Stuart A. , Church, Peter , Feagan, Brian G. , Jairath, Vipul , Jairath, Vipul , Jairath, Vipul , Hyams, Jeffrey S , Shackelton, Lisa M , Rimola, Jordi , Ma, C , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Gee, Michael Stanley , Dillman, Jonathan R , Fletcher, Joel G. , Griffiths, Anne Marie , Greer, Mary‐Louise C.

Mayo Clinic

Inflammatory Bowel Diseases | July 31, 2023 | Volume: 30 | Issue: 3 | Pages: 357-369

10.1093/ibd/izad134 | PMID 37524088 Get It

Abstract Background Perianal fistulas and abscesses occur commonly as complications of pediatric Crohn’s disease (CD). A validated imaging assessment tool for quantification of perianal disease severity and activity is needed to evaluate treatment response. We aimed to identify magnetic resonance imaging (MRI)-based measures of perianal fistulizing disease activity and study design features appropriate for pediatric patients. Methods Seventy-nine statements relevant to MRI-based assessment of pediatric perianal fistulizing CD activity and clinical trial design were generated from literature review and expert opinion. Statement appropriateness was rated by a panel (N = 15) of gastroenterologists, radiologists, and surgeons using modified RAND/University of California Los Angeles appropriateness methodology. Results The modified Van Assche Index (mVAI) and the Magnetic Resonance Novel Index for Fistula Imaging in CD (MAGNIFI-CD) were considered appropriate instruments for use in pediatric perianal fistulizing disease clinical trials. Although there was concern regarding the use of intravascular contrast material in pediatric patients, its use in clinical trials was considered appropriate. A clinically evident fistula tract and radiologic disease defined as at least 1 fistula or abscess on pelvic MRI were considered appropriate trial inclusion criteria. A coprimary clinical and radiologic end point and inclusion of a patient-reported outcome were also considered appropriate. Conclusion Outcomes of treatment of perianal fistulizing disease in children must include MRI. Existing multi-item measures, specifically the mVAI and MAGNIFI-CD, can be adapted and used for children. Further research to assess the operating properties of the indices when used in a pediatric patient population is ongoing.
The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth
Shukla, Sanjeev, Riveros, Carlos , Al-Toubat, Mohammed, Chardon‐Robles, Jonathan, Osumi, Teruko, Serrano, Samuel, Kase, Adam M. , Meurice, Nathalie , Gleba, Justyna, Copland, John A. , Chauhan, Jay, Balaji, K. C., Trynda, Justyna , Balaji, K.C. , Petit, Joachim L. , Gleba, Justyna , Osumi, Teruko, Serrano, Samuel, Fletcher, Steven

Mayo Clinic

Cancers | July 31, 2023 | Volume: 15 | Issue: 15 | Pages: 3851

10.3390/cancers15153851 | PMID 37568667 Get It

Bromodomains (BD) are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation of several genes including protooncogene cellular myelocytomatosis (c-Myc). c-Myc is difficult to target directly by agents due to its disordered alpha helical protein structure and predominant nuclear localization. The epigenetic targeting of c-Myc by BD inhibitors is an attractive therapeutic strategy for prostate cancer (PC) associated with increased c-Myc upregulation with advancing disease. MT-1 is a bivalent BD inhibitor that is 100-fold more potent than the first-in-class BD inhibitor JQ1. MT-1 decreased cell viability and causes cell cycle arrest in G0/G1 phase in castration-sensitive and resistant PC cell lines in a dose-dependent fashion. The inhibition of c-Myc function by MT-1 was molecularly corroborated by the de-repression of Protein Kinase D1 (PrKD) and increased phosphorylation of PrKD substrate proteins: threonine 120, serine 11, and serine 216 amino acid residues in β-Catenin, snail, and cell division cycle 25c (CDC25c) proteins, respectively. The treatment of 3D cell cultures derived from three unique clinically annotated heavily pretreated patient-derived PC xenografts (PDX) mice models with increasing doses of MT-1 demonstrated the lowest IC50 in tumors with c-Myc amplification and clinically resistant to Docetaxel, Cabazitaxel, Abiraterone, and Enzalutamide. An intraperitoneal injection of either MT-1 or in combination with 3jc48-3, an inhibitor of obligate heterodimerization with MYC-associated protein X (MAX), in mice implanted with orthotopic PC PDX, decreased tumor growth. This is the first pre-clinical study demonstrating potential utility of MT-1 in the treatment of PC with c-Myc dysregulation.
O-065 Multicenter investigation into presentation, management and outcome of infectious intracranial aneurysms
Saad, Hassan , Newman, Sarah, Grossberg, Jonathan A , Cawley, C. Michael , Fox, C, Perez-Vaga, C, Burkhardt, Jan‐Karl , Salem, Mohamed M , Jabbour, Pascal , Starke, R, Lu, Victor M. , Levitt, M, Spiotta, Alejandro M , Alawieh, Ali , Dimisko, Laurie , Zohdy, Youssef M. , Pradilla, Gustavo , Jabbour, Pascal , Naamani, Kareem El , Schmidt, Richard F. , Gooch, Michael Reid , Abdelsalam, Ahmed , Levitt, M, Hertzberg, Vicki , Barrow, Daniel L. , Howard, Brian M

Mayo Clinic

SNIS 20th annual meeting oral abstracts | July 30, 2023 | Volume: No volume available | Issue: No issue available | Pages: A51.1-A51

10.1136/jnis-2023-snis.65 Get It

Endovascular stenting techniques for blunt carotid injury
Abdou, Hossam , Stonko, David P. , Kundi, Rishi , Morrison, Jonathan J. , Stonko, David P , Morrison, Jonathan J , Treffalls, Rebecca N.

Mayo Clinic

Vascular | July 27, 2023 | Volume: 32 | Issue: 5 | Pages: 1055-1062

10.1177/17085381231193062 | PMID 37499267 Get It

Objectives While methods of endovascular carotid artery stenting have improved over time, concerns surrounding the safety and efficacy of stenting for blunt carotid injury (BCI) remain. This study aims to present our approach to carotid artery stenting (CAS) by incorporating new technologies such as flow-diverting stents and circuits. Methods There is no robust evidence to support routine carotid artery stenting; however, there are several therapeutic options and approaches for treating BCI that currently require an individualized approach. Endovascular stenting and specific stent selection are largely dictated by the disease process the surgeon intends to treat. We will discuss patient selection, medical management, and the most common revascularization techniques, including transfemoral stenting, trans-carotid arterial revascularization using flow reversal, and stent-assisting coiling. Results It must be stressed that endovascular intervention is not an alternative to or preclusive of antithrombotic or anticoagulant therapy. In the setting of BCI, transfemoral CAS is most appropriate in patients who are symptomatic, have a rapidly progressing or large lesion, and do not have a soft thrombus present due to risk of embolism. Unlike transfemoral CAS, TCAR offers an elegant solution for embolic protection when patients have a soft thrombus present. In the case of a large pseudoaneurysm, we perform stent-assisted coiling. Conclusions We practice selective endovascular intervention, stenting lesions that are flow-limiting or have large or rapidly expanding pseudoaneurysms, and only in patients for whom anticoagulation and antiplatelet agents are not contraindicated. As technology and investigation progress, the concerns regarding the safety and the role of endovascular intervention in the treatment of BCI will be more clearly defined.
Trends in Stimulant and Sedative/Hypnotic Dispensing: An Exploratory Study
Liou, Harris , Leung, Jonathan G. , Mara, Kristin C. , Rummans, Teresa A. , Leung, Jonathan G , Mara, Kristin C , Gentry, Melanie T , Staab, Jeffrey P.

Mayo Clinic

Journal of Attention Disorders | July 27, 2023 | Volume: 27 | Issue: 13 | Pages: 1512-1519

10.1177/10870547231187167 | PMID 37496458 Get It

Objective: To investigate patterns and trends of co-prescriptions of stimulants and sedatives within the last 6 years at a tertiary care center. Method: Patients 18 years of age and older who were dispensed at least one stimulant prescription from an institutional pharmacy between 1/1/2015 and 7/1/2021 were included. Prescription data for any co-prescribed sedative/hypnotic were collected. Results: Both the number of stimulant dispenses and the number of patients with stimulant dispenses increased significantly with yearly incidence rate ratios of 1.115 (95% CI [1.110, 1.119]) and 1.090 (95% CI [1.084, 1.096]), respectively. The number of patients with a stimulant dispensed who also had a benzodiazepine or “Z-drug” sedative-hypnotic dispensed at any point in the search timeframe increased significantly with incidence rate ratios of 1.077 and 1.092, respectively. The number of stimulant dispenses, number of patients with stimulant dispenses, and number of patients with a stimulant dispensed who also had both a benzodiazepine and Z-drug dispensed at any point in the search timeframe increased significantly more in Non-White than in White patients. Conclusions: The results confirm previous findings of increases in dispensing of stimulants over the past 6 years and report increased polypharmacy of stimulants and sedative-hypnotics.
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Parodis, Ioannis , Sen, Parikshit , Ravichandran, Naveen , Day, Jessica , Joshi, Mrudula , Jagtap, Kshitij , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Colunga-Pedraza, I. J. , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Gupta, Vikas , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danieli, Maria Giovanna , Giollo, Alessandro, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos, Aharonov, Or, bouchti, Imane El, Baba, Zineb, Maurier, François, Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Giollo, Alessandro , Gupta, Latika , Agarwal, Vishwesh , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Gutiérrez, Carlos Enrique Toro , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Saavedra, Miguel A , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Joshi, Mrudula , Day, Jessica , Parodis, Ioannis , Nune, Arvind , Naveen, R , Agarwal, Vikas , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , Sen, Parikshit , Andreoli, Laura , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Agarwal, Vishwesh , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Makol, Ashima , Barman, Bhupen , Torre, Ignacio García‐De La , Goo, Phonpen Akawatcharangura , Chen, Yi‐Ming , Halabi, Hussein , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Pilania, Rakesh Kumar , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Alunno, Alessia , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira, Kimura, Naoki, Gono, Takahisa , Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Giannini, Margherita , Maurier, F. , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , So, Ho , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | July 25, 2023 | Volume: 63 | Issue: 5 | Pages: 1341-1351

10.1093/rheumatology/kead382 | PMID 37505460 Get It

Abstract Objectives We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods Delayed-onset (&gt;7 days) vaccine-related adverse events (AE), disease flares and AID-related treatment modifications were analysed upon diagnosis of AID vs healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine. Results Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, P = 0.01; minor AE 40% vs 25.9%, P = 0.03; major AE 17.5% vs 4.6%, P &lt; 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination disease flares were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a disease flare were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively. Conclusion This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and for the fetus by passive immunization appear to outweigh potential risks.
Anakinra‐Associated Systemic Amyloidosis
Alehashemi, Sara , Dasari, Surendra , Metpally, Anvitha , Uss, Kat, Chen, Marcus Y. , Ahlman, Mark A. , Kim, Jeff , Wargo, Susannah, Kuhns, Douglas B. , Fink, Danielle , Jesus, Adriana de, Martin, Paul S. , Bolaños, Jonathan A. , Nasr, Samih H. , Goldbach‐Mansky, Raphaela , Goldbach-Mansky, Raphaela , McPhail, Ellen, Castelo‐Soccio, Leslie , Heller, Theo , Kellman, Peter , Chang, Richard Cheng-An , Lee, Chyi‐Chia Richard , McPhail, Ellen Darcy

Mayo Clinic

Arthritis & Rheumatology | July 25, 2023 | Volume: 76 | Issue: 1 | Pages: 100-106

10.1002/art.42664 | PMID 37488949 Get It

ObjectiveTo describe a 41‐year‐old woman with a history of neonatal onset multisystem inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin‐1 receptor antagonist (IL‐1Ra) protein, anakinra, since the age of 28, who presented with golf‐ball size nodules at the anakinra injection sites, early satiety, new onset nephrotic syndrome in the context of normal markers of systemic inflammation.MethodsClinical history and histologic evaluation of biopsies of skin, gastric mucosa, and kidney with Congo‐red staining and proteomic evaluation of microdissected Congo red–positive amyloid deposits by liquid chromatography‐tandem mass spectrometry.ResultsThe skin, stomach, and kidney biopsies all showed the presence of Congo red–positive amyloid deposits. Mass spectrometry‐based proteomics demonstrated that the amyloid deposits in all sites were of AIL1RAP (IL‐1Ra protein)‐type. These were characterized by high spectral counts of the amyloid signature proteins (apolipoprotein AIV, apolipoprotein E, and serum amyloid P‐component) and the amyloidogenic IL‐1Ra protein, which were present in Congo red–positive areas and absent in Congo red–negative areas. The amino acid sequence identified by mass spectrometry confirmed that the amyloid precursor protein was recombinant IL‐1Ra (anakinra) and not endogenous wild‐type IL‐1Ra.ConclusionThis is the first report of iatrogenic systemic amyloidosis due to an injectable protein drug, which was caused by recombinant IL1Ra (anakinra).
Usability and feasibility of PreventS-MD web app for stroke prevention
Feigin, Valery L. , Krishnamurthi, Rita , Medvedev, Oleg N. , Merkin, Alexander, Nair, Balakrishnan, Jalili-Moghaddam, Shabnam, Barker‐Collo, Suzanne , Ratnasabapathy, Yogini , Skinner, Luke C , Sachdev, Perminder S. , Brainin, Michael , Hankey, Graeme J. , Azarpazhooh, Reza, Bhatia, Anjali , Budinčević, Hrvoje , Child, Nicholas, Chwojnicki, Kamil , Correia, Manuel, Davis, Alan , Devlin, Gerry , Demarin, Vida , Dhamija, Rajinder K. , Ding, Ding , Докова, Клара , Dudley, Makarena , Dyer, Jesse, Edmonds, Misty , Ely, Marcela , Feigin, Svetlana , Fornolles, C, Gall, Seana , Gil, Artyom , George, Ann, Haršány, Michal , Harwood, Matire, Hou, Zeng‐Guang , Ibrahim, Norlinah Mohamed, Ka‘ai, Tania , Kalra, Nidhi , Katzenellenbogen, Judith , Kang, Law Zhe, Kar, Arindam , Kazin, Vitalij, Kamenova, Saltanat , Kondybaeva, A., Lavados, Pablo M, Lee, Tsong‐Hai , Liu, Liping , Mahawish, Karim , Maluchnik, Michał , Martins, Sheila , Mavaddat, Nahal , Mehndiratta, Man Mohan, Oliver, Angela , Öztürk, Şerefnur , Patel, Nikhil, Prakash, B, Roos, Kev, Sekaran, Lakshmanan , Shamalov, N. А. , Solomon, Alina, Suwanwela, Nijasri C., Volevach, Ekaterina , Volný, Ondřej , Wan, Joyce, Withanapathirana, Katila, Welte, Tamara, Wiebers, David O. , Zaidi, Wan Asyraf Wan , Kravchenko, Michael , Barker-Collo, Suzanne , Owolabi, Mayowa , Sachdev, Perminder S , Brainin, Michael , Thrift, Amanda , Hankey, Graeme J , Katzenellenbogen, Judith M , Nair, Balakrishnan, Kravchenko, Michael , Jalili‐Moghaddam, Shabnam , Norrving, Bo , Arroll, Bruce , Thrift, Amanda G. , Abd-Allah, Foad , Akinyemi, Rufus , Bath, Philip M. , Brayne, Carol , Child, Nicholas, Farhoudi, Mehdi , Aziz, Aznida Firzah Abdul , Gabriel, Denis , Gnedovskaya, Elena V. , Harwood, Matire L. N. , Hillis, Argye Elizabeth , Hwang, Kevin O. , Ibrahim, Norlinah Mohamed , Kalra, Nidhi, Karaszewski, Bartosz , Kivipelto, Miia , Lavados, Pablo M. , Mateen, Farrah J. , Mikulík, Robert , Oliver, Angela, Patel, Nikhil, Пирадов, М. А. , Purvis, Tara L. , Reips, Ulf‐Dietrich , Rosand, Jonathan M. , Sahathevan, Ramesh , Silva, Deidre Anne De , Singh, Vinod, Srivastava, M.V. Padma , Taylor, Denise M. , Truelsen, Thomas Clement , Venketasubramanian, Narayanaswamy , Winkler, Andrea Sylvia , Wijeratne, Tissa , Wu, Teddy Y

Mayo Clinic

International Journal of Stroke | July 24, 2023 | Volume: 19 | Issue: 1 | Pages: 94-104

10.1177/17474930231190745 | PMID 37485871 Get It

Background: Most strokes and cardiovascular diseases (CVDs) are potentially preventable if their risk factors are identified and well controlled. Digital platforms, such as the PreventS-MD web app (PreventS-MD) may aid health care professionals (HCPs) in assessing and managing risk factors and promoting lifestyle changes for their patients. Methods: This is a mixed-methods cross-sectional two-phase survey using a largely positivist (quantitative and qualitative) framework. During Phase 1, a prototype of PreventS-MD was tested internationally by 59 of 69 consenting HCPs of different backgrounds, age, sex, working experience, and specialties using hypothetical data. Collected comments/suggestions from the study HCPs in Phase 1 were reviewed and implemented. In Phase 2, a near-final version of PreventS-MD was developed and tested by 58 of 72 consenting HCPs using both hypothetical and real patient (n = 10) data. Qualitative semi-structured interviews with real patients (n = 10) were conducted, and 1 month adherence to the preventive recommendations was assessed by self-reporting. The four System Usability Scale (SUS) groups of scores (0–50 unacceptable; 51–68 poor; 68–80.3 good; >80.3 excellent) were used to determine usability of PreventS-MD. Findings: Ninety-nine HCPs from 27 countries (45% from low- to middle-income countries) participated in the study, and out of them, 10 HCPs were involved in the development of PreventS before the study, and therefore were not involved in the survey. Of the remaining 89 HCPs, 69 consented to the first phase of the survey, and 59 of them completed the first phase of the survey (response rate 86%), and 58 completed the second phase of the survey (response rate 84%). The SUS scores supported good usability of the prototype (mean score = 80.2; 95% CI [77.0–84.0]) and excellent usability of the final version of PreventS-MD (mean score = 81.7; 95% CI [79.1–84.3]) in the field. Scores were not affected by the age, sex, working experience, or specialty of the HCPs. One-month follow-up of the patients confirmed the high level of satisfaction/acceptability of PreventS-MD and (100%) adherence to the recommendations. Interpretation: The PreventS-MD web app has a high level of usability, feasibility, and satisfaction by HCPs and individuals at risk of stroke/CVD. Individuals at risk of stroke/CVD demonstrated a high level of confidence and motivation in following and adhering to preventive recommendations generated by PreventS-MD.